<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00967343</url>
  </required_header>
  <id_info>
    <org_study_id>CR-AIR-004</org_study_id>
    <secondary_id>EudraCT no. 2008-008198-73</secondary_id>
    <nct_id>NCT00967343</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor</brief_title>
  <official_title>An Open-label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR), Through the Use of TH9402 and Light Treatment in an ex Vivo Process, in Patients Receiving a CD34-selected Peripheral Blood Stem Cell Graft From a Related, Haploidentical Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiadis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kiadis Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the administration of a donor lymphocyte
      preparation depleted of functional host alloreactive T-cells (ATIR) after a T-cell depleted
      stem cell transplant from a related, haploidentical donor enhances survival by improving the
      immune effect against infections while preventing graft-versus-host disease .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic stem cell transplantation is the treatment of choice for many patients with
      leukemia and other hematologic malignancies. However, a major limitation of this therapy is
      that for a significant number of patients no fully HLA-matched donor can be found. The
      application of partially HLA-matched (haploidentical) family donors, who are virtually always
      available, has some complications. If there is no T-cell add-back it increases the risk for
      life-threatening infections and disease relapse, while in case of T-cell add-back the risk
      for graft-versus-host disease is raised.

      Kiadis Pharma has developed a method to selectively deplete host alloreactive T-cells through
      photodynamic therapy, using TH9402 ex vivo. The donor lymphocyte preparation depleted of
      functional host alloreactive T-cells (ATIR) is administered to the patient 28-42 days after
      the stem cell transplant.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>6 and 12 months after the transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute and chronic graft-versus-host disease</measure>
    <time_frame>Up to 24 months after the transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 24 months after the transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of bacterial, viral or fungal infection</measure>
    <time_frame>Up to 24 months after the transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>Up to 24 months after the transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status (including Quality of Life)</measure>
    <time_frame>Up to 24 months after the transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 24 months after the transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Myeloid Leukemia</condition>
  <condition>Lymphoblastic Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Disorders</condition>
  <arm_group>
    <arm_group_label>ATIR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor lymphocyte preparation depleted of host functional alloreactive T-cells</intervention_name>
    <description>Single intravenous infusion with 2x10E6 T-cells/kg</description>
    <arm_group_label>ATIR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        One of the following hematological malignancies:

          -  Acute Myeloid Leukemia (AML)

          -  Acute Lymphoblastic Leukemia (ALL)

          -  Myelodysplastic Syndrome (MDS)

          -  Ph-positive chronic myeloid leukemia (CML)

          -  Non-Hodgkin Lymphoma (NHL)

          -  Myelodysplastic Syndrome (MDS)

          -  Chronic Myeloid Leukemia (CML)

          -  Multiple Myeloma (MM)

          -  Chronic Lymphocytic Leukemia (CLL)

          -  Myeloproliferative Syndrome (MPS)

        Exclusion Criteria:

          -  AML in 1st complete remission with good risk karyotypes

          -  MM featuring concurrent extramedullar disease or being non-responsive to prior therapy

          -  CML in blast crisis

          -  CLL concurrently transformed into high-grade lymphoma and failing to demonstrate at
             least partial remission

          -  NHL with concurrent bulky disease (≥ 5 cm)

          -  Diffusing Capacity for Carbon Monoxide (DLCO) &lt; 40% predicted

          -  Left ventricular ejection fraction &lt; 40%

          -  AST/SGOT &gt; 2.5 x ULN

          -  Bilirubin &gt; 1.5 x ULN

          -  Creatinine &gt; 1.5 x ULN

          -  HIV positive

          -  Positive pregnancy test for women of childbearing age

          -  Prior haploidentical peripheral blood stem cell or cord blood transplantation

          -  Less than 2 years from a prior allogeneic stem cell transplantation

          -  Estimated probability of surviving less than three months

          -  Major anticipated illness or organ failure incompatible with survival from transplant

          -  Severe psychiatric illness or mental deficiency sufficiently severe as to make
             compliance with the transplant treatment unlikely and informed consent impossible

          -  Known allergy to any of the components of ATIR

          -  Any other condition which, in the opinion of the investigator, makes the patient
             ineligible for the study

        Donor Inclusion Criteria:

          -  Haploidentical family donor with 2 to 3 mismatches at the HLA-A, -B and/or DR loci of
             the unshared haplotype.

          -  Male or female, age ≥ 16, ≤ 75 years.

          -  Donors must be fit to receive G-CSF and undergo apheresis (normal blood count,
             normotensive and no history of stroke).

          -  Donor must have Eastern Cooperative Oncology Group (ECOG) performance status of 2 or
             less.

          -  Donor must provide written informed consent.

        Donor Exclusion Criteria:

          -  Medically uncontrolled coronary heart disease.

          -  Myocardial infarction within the last 3 months.

          -  History of uncontrolled seizures.

          -  History of malignancy (except basal cell or squamous carcinoma of the skin, positive
             PAP smear and subsequent negative follow up).

          -  Positive test result for any of the mandatory viral tests in the applicable region,
             except for a positive cytomegalovirus (CMV) result, which does not lead to exclusion.

          -  Presence of a transmissible disease (such as HIV positive), a major illness, a
             suspected systemic dysfunction and/or an active inflammatory or autoimmune disorder.

          -  Female donors who are pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Mielke, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Julius Maximilian University of Würzburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denis-Claude Roy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maisonneuve-Rosemont Hospital, Montreal, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Velardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Perugia, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katy Rezvani, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Hospital, London, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University, Comprehesive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Université Libre de Bruxelles - Institute Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Liege - CHU Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HHSC, Henderson Hospital Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ontario Cancer Institute / Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Medizinische UNI-Klinik</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikums Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perugia University</name>
      <address>
        <city>Perugia</city>
        <zip>06123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 ONN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2009</study_first_submitted>
  <study_first_submitted_qc>August 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <disposition_first_submitted>March 22, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>March 22, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 1, 2013</disposition_first_posted>
  <last_update_submitted>March 22, 2013</last_update_submitted>
  <last_update_submitted_qc>March 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haploidentical stem cell transplantation</keyword>
  <keyword>Graft-versus-host disease</keyword>
  <keyword>Immune reconstitution</keyword>
  <keyword>Alloreactive T-cells</keyword>
  <keyword>Photodepletion</keyword>
  <keyword>TH9402</keyword>
  <keyword>Transplant related mortality</keyword>
  <keyword>Hematologic malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

